Achieving a one-year-tumor-free survival in a female with primary large cell neuroendocrine carcinoma of the urinary bladder and liver metastasis; a case report

Nastaran Mahmoudnejad; Peyman Mohammadi Torbati; Alireza Lashay; Navid Ahmadi; Fateme Guitynavard

doi:10.1016/j.eucr.2023.102347

Achieving a one-year-tumor-free survival in a female with primary large cell neuroendocrine carcinoma of the urinary bladder and liver metastasis; a case report

Urol Case Rep. 2023 Feb 2:47:102347. doi: 10.1016/j.eucr.2023.102347. eCollection 2023 Mar.

Authors

Nastaran Mahmoudnejad¹, Peyman Mohammadi Torbati², Alireza Lashay¹, Navid Ahmadi³, Fateme Guitynavard⁴

Affiliations

¹ Urology and Nephrology Research Center, Shahid Beheshti University of Medical Science, Tehran, Iran.
² Department of Pathology, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
³ Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.
⁴ Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Abstract

Primary neuroendocrine tumor (NET) of bladder is rare. It has four subtypes, and large cell neuroendocrine carcinoma (LCNEC) is the rarest. LCNEC affects mostly men over 60. Most common symptom is gross hematuria. It has no specific treatment. Metastasis is common and once occurred, average survival would be less than three months. Herein we present diagnostic and therapeutic management of a 65-year-old female with LCNEC of bladder and concurrent high-grade urothelial carcinoma. Despite developing early liver metastasis, she achieved a one-year tumor-free survival.

Keywords: Bladder tumor; LCNEC; Large cell neuroendocrine carcinoma; Primary NET; Primary neuroendocrine tumor.

Publication types

Case Reports